RU-58841 (Hair Serum)

What is RU-58841 (5%)?

RU-58841 (known chemically as PSK-3841 or HMR-3841) is a high-affinity, non-steroidal selective androgen receptor modulator (SERM) that functions as a pure competitive antagonist at the androgen receptor subsite. Formulated specifically at a 5% concentration, this product is engineered as a pre-solubilized topical liquid.  Designed for direct application within cell culture and localized tissue assays. Because it is delivered ready-to-use within a optimized chemical vehicle, it does not require a reconstitution before application. Researchers utilize this compound primarily in topical follicular research models.  It can be used to evaluate the localized protection of hair follicles from androgen-mediated miniaturization.

For laboratory evaluation and in vitro testing, researchers frequently choose to buy RU-58841 (5%) to ensure uniform concentration metrics across follicular target arrays. To prevent evaporation or thermal degradation of the pre-solubilized carrier matrix, the container must be sealed tightly and stored in a cool, light-protected environment.

Chemical and Molecular Data

What are the Mechanisms of Action?

The biochemical pathways and cellular targets of RU-58841 within topical follicular research models include:

• Competitive Androgen Receptor Antagonism: Research demonstrates that RU-58841 binds to the ligand-binding domain of the androgen receptor (AR).  It has an affinity that matches or exceeds native testosterone and dihydrotestosterone (DHT). By occupying this subsite, it competitively blocks endogenous androgens from anchoring to the receptor.
• Follicular Receptor Shielding: In follicular models, the localized presence of the 5% solution acts as a physical chemical shield over the dermal papilla cells. This blocks the downstream transcriptional signaling cascades that trigger follicle miniaturization, structural weakening of the hair shaft, and premature entry into the telogen growth phase.
• Localized Metabolic Isolation: Studies indicate that when applied topically, the compound exerts its anti-androgenic effects locally within the target follicular structures. In vitro tissue processing reveals high retention within the pilosebaceous unit.  This enables targeted isolation without affecting systemic androgen populations.

What are the Clinical & Preclinical Trials on RU-58841?

When evaluating research efficacy and published experimental literature for RU-58841:

• Follicular Micro-Rescue Evaluations: Preclinical investigations published in major dermatological research archives evaluated RU-58841 applications within macaque models exhibiting androgenetic alopecia. The data demonstrated that topical application triggered significant increases in anagen follicle counts, driving visible follicle recovery and shaft diameter normalization.
• Topical Bio-Availability and Matrix Penetration: Pharmacokinetic evaluations tracking the pre-solubilized solution confirm that the compound efficiently penetrates the stratum corneum.  This leads to concentration inside local sebaceous pathways. Crucially, analytical screening confirms that the 5% concentration achieves maximum target receptor saturation without spilling active metabolites into baseline systemic circulation.
• Dose-Response Follicular Consistency: Across comparative in vitro cell line arrays, RU-58841 demonstrates a highly linear dose-dependent suppression of androgen-induced apoptotic markers. This provides laboratory teams with highly repeatable screening dynamics across varying cellular stresses.

How does RU-58841 compare to other compounds?

To evaluate target specificity, delivery optimization, and localized vs. systemic mechanics, researchers compare RU-58841 against alternative follicular restoration agents and enzyme inhibitors: